These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Listed as ongoing, but also has a completion date and reported results 2004-001778-21 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Of A Novel CCR5 Antagonist, UK-427,857, In Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone F... 2011-04-19 bad-data
Listed as ongoing, but also has a completion date and reported results 2004-001914-15 A Multicenter, Randomized, Double-Blind, Comparative Trial Of A Novel CCR5 Antagonist, UK-427,857, In Combination With Zidovudine/Lamivudine Versus Efavirenz In Combination With Zidovudine/Lamivudi... 2012-12-13 bad-data
Ongoing, reported early 2008-006873-33 AN OPEN-LABEL, MULTICENTER, MULTIPLE-DOSE PHARMACOKINETIC AND 48-WEEK SAFETY AND EFFICACY TRIAL OF MARAVIROC IN COMBINATION WITH OPTIMIZED BACKGROUND THERAPY FOR THE TREATMENT OF ANTIRETROVIRAL-EXP... not-yet-due
Listed as ongoing, but also has a completion date and reported results 2008-007038-24 "Estudio piloto de una nueva combinación de maraviroc + atazanavir/ritonavir frente a atazanavir/ritonavir + emtricitabina/tenofovir para el tratamiento de pacientes con infección por VIH del tipo VIH... 2011-07-22 bad-data
Reported results 2009-010269-21 A Phase IIb study to select a once daily oral dose of GSK1349572 administered with either abacavir/lamivudine or tenofovir/emtricitabine in HIV-1 infected antiretroviral therapy naïve adult subjects. 2016-12-22 due-trials
Listed as ongoing, but also has a completion date and reported results 2009-017950-11 A Phase III, randomized, double blind study of the safety and efficacy of GSK1349572 50 mg once daily to raltegravir 400 mg twice daily both administered with fixed-dose dual nucleoside reverse transc... 2016-12-27 bad-data
Reported results 2009-017951-87 A Phase III study to demonstrate the antiviral activity and safety 2015-05-25 due-trials
Listed as ongoing, but also has a completion date 2009-018001-51 A Phase III Randomized, Double-blind Study of the Safety and Efficacy of GSK1349572 50 mg Once Daily Versus Raltegravir 400 mg Twice Daily, Both Administered with an Investigator-selected Background R... 2015-03-03 bad-data
Listed as ongoing, but also has a completion date and reported results 2010-018487-16 Estudio de fase IIb para seleccionar una dosis oral diaria de GSK2248761 en combinación con tenofovir/emtricitabina o abacavir/lamivudina, en sujetos adultos infectados por el VIH-1 que no han recibid... 2011-05-01 bad-data
Listed as ongoing, but also has a completion date and reported results 2010-018532-40 A Phase 2b study to select a once daily oral dose of GSK2248761 in HIV-1 infected antiretroviral therapy experienced adults with non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance 2011-07-19 bad-data
Listed as ongoing, but also has a completion date and reported results 2010-020983-39 A Phase 3, randomized, double-blind study of the safety and efficacy of GSK1349572 plus abacavir/lamivudine fixed-dose combination therapy administered once daily compared to Atripla over 96 weeks in ... 2015-12-03 bad-data
Listed as ongoing, but also has a completion date and reported results 2010-021785-30 A MULTICENTER, RANDOMIZED, DOUBLE BLIND, COMPARATIVE TRIAL OF MARAVIROC + DARUNAVIR/RITONAVIR VERSUS EMTRICITABINE/TENOFOVIR + DARUNAVIR/RITONAVIR FOR THE TREATMENT OF ANTIRETROVIRAL NAÏVE HIV INFECTE... 2014-01-28 bad-data
Listed as ongoing, but also has a completion date and reported results 2010-021994-35 A Multicenter, Randomized, Blinded, Placebo Controlled Study To Evaluate The Safety Of Maraviroc In Combination With Other Antiretroviral Agents In HIV-1 Infected Subjects Coinfected With Hepatitis C ... 2015-03-24 bad-data
Reported results 2011-000437-36 A Phase IIb Randomized, Controlled, Partially-Blinded Trial to Investigate Safety, 2017-05-12 due-trials
Ongoing 2011-001646-16 A Dolutegravir Open Label Protocol for HIV infected, Adult and Adolescents Patients with Integrase Resistance not-yet-due
Not reported 2011-003303-38 Observational Drug Exposure Registry for Long-Term Follow-Up of Subjects Exposed to GSK2248761 2013-02-19 due-trials
Reported results 2011-003629-86 A Phase IIIb, randomized, open-label study of the safety and efficacy of GSK1349572 (dolutegravir, DTG) 50 mg once daily compared to darunavir/ritonavir (DRV/r) 800 mg/100 mg once daily each administe... 2016-12-26 due-trials
Not reported 2011-004435-31 An Expanded Access Protocol for Subjects Who Have 2016-08-31 due-trials
Ongoing, reported early 2012-005823-34 A Phase IIIb, randomized, open-label study of the safety and not-yet-due
Ongoing, reported early 2013-000783-29 A Phase IIb Study Evaluating a Long-Acting Intramuscular Regimen of GSK1265744 plus TMC278 For The Maintenance of Virologic Suppression Following an Induction of Virologic Suppression on an Oral regim... not-yet-due
Completed, but no date 2013-003527-11 ING200336: A Prospective, Interventional Pharmacokinetic and Safety Study of DTG/ABC/3TC in Pregnant Women. bad-data
Reported results 2013-005487-26 A Phase 2b Randomized, Active-Controlled, Double-Blind Trial to Investigate Safety, Efficacy and Dose-response of BMS-955176, Given on a Backbone of Tenofovir/Emtricitabine, in Treatment-Naive HIV-1 I... 2017-08-21 due-trials
Ongoing, reported early 2014-002111-41 A Multi-arm Phase 3 Randomized Placebo Controlled Double Blind Clinical Trial to Investigate the Efficacy and Safety of BMS-663068/GSK3684934 in Heavily Treatment Experienced Subjects Infected with Mu... not-yet-due
Ongoing, reported early 2014-005147-40 A Phase III, randomized, multicenter, parallel-group, noninferiority study evaluating the efficacy, safety, and tolerability of switching to dolutegravir plus rilpivirine from current INI-, NNRTI-, or... not-yet-due
Ongoing, reported early 2014-005148-16 A Phase III, randomized, multicenter, parallel-group, noninferiority study evaluating the efficacy, safety, and tolerability of switching to dolutegravir plus rilpivirine from current INI-, NNRTI-, or... not-yet-due
Ongoing 2015-004401-17 A Phase III, randomized, multicenter, parallel-group, non-inferiority study evaluating the efficacy, safety, and tolerability of switching to dolutegravir plus lamivudine in HIV-1 infected adults who ... not-yet-due
Ongoing 2015-004418-95 A Phase III, randomised, double-blind, multicentre, parallel-group, non-inferiority study evaluating the efficacy, safety, and tolerability of dolutegravir plus lamivudine compared to dolutegravir plu... not-yet-due
Ongoing 2016-000459-28 A Phase III, randomised, double-blind, multicentre, parallel-group, non-inferiority study evaluating the efficacy, safety, and tolerability of dolutegravir plus lamivudine compared to dolutegravir plu... not-yet-due
Ongoing 2016-001646-25 A Phase III, Randomized, Multicenter, Parallel-group, Open- Label Study Evaluating the Efficacy, Safety, and Tolerability of Long-Acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of V... not-yet-due
Ongoing 2016-001647-39 A Phase III, randomized, multicenter, parallel-group, noninferiority, open-label study evaluating the efficacy, safety, and tolerability of switching to long-acting cabotegravir plus longacting rilpiv... not-yet-due
Ongoing 2017-002946-62 A Phase IIIb, Randomized, Multicenter, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Long-acting Cabotegravir Plus Long-acting Rilpivirine Admi... not-yet-due